The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials
出版年份 2018 全文链接
标题
The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials
作者
关键词
-
出版物
Cancer Medicine
Volume 7, Issue 5, Pages 1642-1659
出版商
Wiley
发表日期
2018-03-24
DOI
10.1002/cam4.1387
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
- (2017) Kevin J Harrington et al. LANCET ONCOLOGY
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- Real-world data on nivolumab treatment of non-small cell lung cancer
- (2016) O.T. Brustugun et al. ACTA ONCOLOGICA
- Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy
- (2016) P. Bidoli et al. ANNALS OF ONCOLOGY
- Personalized PD-1/PD-L1 inhibitor therapy for advanced non small cell lung cancer beyond first line; a meta-analysis of potential predictive factors
- (2016) O.M. Abdel-Rahman ANNALS OF ONCOLOGY
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Naiyer A. Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials
- (2016) Jiaxing Huang et al. OncoTargets and Therapy
- Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers
- (2016) Arun Rajan et al. Human Vaccines & Immunotherapeutics
- Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence
- (2016) Joline S. J. Lim et al. Therapeutic Advances in Respiratory Disease
- PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
- (2016) Claud Grigg et al. Journal for ImmunoTherapy of Cancer
- Meta-analysis of incidence rate data in the presence of zero events
- (2015) Matthew J Spittal et al. BMC Medical Research Methodology
- PD-1 Blockers
- (2015) Jedd D. Wolchok CELL
- Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data
- (2015) Lesley A. Stewart et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy
- (2015) Ninh M. La-Beck et al. PHARMACOTHERAPY
- Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy
- (2014) Erika Rijavec et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
- (2014) S.S. Ramalingam et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy
- (2014) N.A. Rizvi et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)
- (2014) S.J. Antonia et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Cancer immunotherapies, their safety and toxicity
- (2013) Gheath Alatrash et al. Expert Opinion On Drug Safety
- What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
- (2012) M. Reck ANNALS OF ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors
- (2008) Syed Asad Ali et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now